Platinum agent combination treatment for triplenegative breast cancer well tolerated in clinical trial

| April 7, 2015 | 0 Comments

Research from Rutgers Cancer Institute of New Jersey shows that a combination of doxil, carboplatin and bevacizumab is a well-tolerated treatment regimen in patients with metastatic triple-negative breast cancer who received no prior treatment for their metastatic disease. read more

Follow this link:
Platinum agent combination treatment for triplenegative breast cancer well tolerated in clinical trial

Tags: , , , , , , , , , ,

Category: Recent News

About the Author ()

Leave a Reply